Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10826161 | 0.98 | L3MBTL1 (0.54) | TSHRL3MBTL1TDP1HRH4HRH3 | |
| SCHEMBL10825883 | 0.98 | L3MBTL1 (0.54) | TSHRL3MBTL1TDP1HRH4HRH3 | |
| SCHEMBL3289641 | 0.98 | L3MBTL1 (0.54) | TSHRL3MBTL1TDP1HRH4HRH3 | |
| SCHEMBL6941525 | 0.98 | L3MBTL1 (0.54) | TSHRL3MBTL1TDP1HRH4HRH3 | |
| SCHEMBL31018369 | 0.94 | L3MBTL1 (0.51) | TSHRL3MBTL1TDP1HRH4HRH3 | |
| SCHEMBL1001167 | 0.94 | TSHR (0.58) | TSHRL3MBTL1TDP1HRH4HRH3 | |
| SCHEMBL31018373 | 0.93 | L3MBTL1 (0.50) | TSHRL3MBTL1TDP1HRH4HRH3 | |
| SCHEMBL8998380 | 0.92 | TSHR (0.56) | TSHRL3MBTL1TDP1HRH4HRH3 | |
| SCHEMBL14673636 | 0.90 | TSHR (0.50) | TSHRL3MBTL1TDP1HRH4HRH3 | |
| SCHEMBL2640223 | 0.89 | TSHR (0.70) | TSHRL3MBTL1TDP1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119331511-A | Environment-friendly bidirectional three-dimensional waterproof moisture-permeable film spreading material and preparation method thereof | 诸暨市捷达新材料有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-119331511-A | Environment-friendly bidirectional three-dimensional waterproof moisture-permeable film spreading material and preparation method thereof | 诸暨市捷达新材料有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| CN-1143858-C | 6, 9-disubstituted 2- [ trans- (aminocyclohexyl) amino ] purines, compositions and uses thereof | ������ҩ������˾ | 2004-03-31 | — | — | CN | disclosed |
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| WO-2002030897-A2 | COMPOSITIONS AND METHODS FOR REGULATING THE NERVOUS SYSTEM | FILLION GILLES (FR) | 2002-04-18 | — | — | WO | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| US-4866206-A | INHIBITORS OF ORNITHINE DECARBOXYLASE | MERRELL DOW FRANCE ET CIE (FR) | 1989-09-12 | — | — | US | disclosed |
| US-4743691-A | INHIBITORS OF ORNITHINE DECARBOXYLASE | MERRELL DOW FRANCE ET CIE (FR) | 1988-05-10 | — | — | US | disclosed |
| EP-0046710-B1 | PREPARATION OF AMINOACETONITRILE DERIVATIVES | MERRELL TORAUDE ET COMPAGNIE (FR) | 1984-06-13 | — | — | EP | disclosed |
| US-4405530-A | Process for preparing fluorinated amino-nitriles | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-09-20 | — | — | US | disclosed |
| EP-0046710-A1 | Preparation of aminoacetonitrile derivatives | MERRELL TORAUDE ET COMPAGNIE (FR) | 1982-03-03 | — | — | EP | disclosed |
| US-4174458-A | Novel analogues of prostanoic acids not occurring in nature | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-11-13 | — | — | US | disclosed |
| US-4098815-A | BRONCHODILATOR AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | TSHR 4411/4885L3MBTL1 1139/4885TDP1 210/4885 |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | NR3C2, MC2R, NR3C1 | TSHR 75/4885L3MBTL1 3052/4885TDP1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.